{
    "clinical_study": {
        "@rank": "45166", 
        "arm_group": [
            {
                "arm_group_label": "Conventional treatment arm", 
                "arm_group_type": "Active Comparator", 
                "description": "10 Adult (aged above 18) transfusion-dependent patients with AA and serum ferritin < 1000 mg/L undergoing treatment programs of immunosuppressive treatment (Cyclosporine A)"
            }, 
            {
                "arm_group_label": "Exjade treatment arm", 
                "arm_group_type": "Experimental", 
                "description": "15 transfusion-dependent adult (aged above 18) patients with AA and serum ferritin \u2265 1000 mg/L undergoing treatment programs of immunosuppressive treatment (Cyclosporine A) and Exjade"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate Exjade efficacy and safety in patients with aplastic anemia and\n      transfusion-dependent iron overload, undergoing treatment programs of immunosuppressive\n      treatment (Cyclosporine A) , in comparison with a group of patients undergoing treatment\n      programs of immunosuppressive treatment (Cyclosporine A) without chelation therapy."
        }, 
        "brief_title": "Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Aplastic Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Aplastic", 
                "Iron Overload"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Main diagnosis: aplastic anemia\n\n          -  Absence of severe and/or uncontrolled comorbidities\n\n          -  Confirmed iron overload (serum ferritin  \u2265 1000 mkg/L)\n\n          -  Serum creatinine is not higher than the upper limit of normal for the given age\n\n          -  Absence of severe proteinuria. Protein/Creatinine ratio should be < 0.5 mg/mg\n\n          -  Liver enzymes are < 5 ULN\n\n          -  Completion of a scheduled cycle of immunosuppressive treatment program, with no\n             severe infectious or generalized hemorrhagic complications\n\n          -  WHO (ECOG) performance status \u2264 2\n\n        Exclusion Criteria:\n\n          -  No signed informed consent form\n\n          -  Patient is under 18 years old\n\n          -  Severe concomitant condition\n\n          -  Severe infectious and generalized haemorrhagic complication following regular planned\n             cycle of programmed immune suppressive treatment.\n\n          -  History of increased sensitivity to active substance and any other ingredient of the\n             medicinal product.\n\n          -  Creatinine clearance (CC) < 60 ml/min and/or creatinine concentration in blood serum\n             is 2 or more times higher than upper limit of age normal by results of 2 tests at\n             Visits 1 and 2.\n\n          -  Severe liver disorders (class C by Child-Pugh scale).\n\n          -  Patients with aplastic anaemia in which chelator treatment will be ineffective due to\n             rapid progression of the disease.\n\n          -  Significant proteinuria basing on protein creatinine ratio > 1.0 mg/ml in urine\n             sample from second urination at Visits 1 and 2 (or as an alternative in 2 of 3 urine\n             samples at screening);\n\n          -  Rare hereditary disorders related to galactose intolerance, severe deficit of lactase\n             or glucose-galactose malabsorption;\n\n          -  Pregnancy, lactation;\n\n          -  Level of liver enzymes higher than 5 upper limits of age normal at Visits 1 and 2."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818726", 
            "org_study_id": "CICL670ARU02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Exjade treatment arm", 
                "description": "In the investigational arm all patients recieve a standard immunosuppressant (Cyclosporine A). The starting dose of Exjade will be 20 mg/kg/day with up- and down-titration steps of 5-10 mg/kg/day if necessary, depending on serum ferritin, tolerability and comorbidities. Doses above 30 mg/kg are discouraged as such experience is limited in aplastic anemia. Patients are to take Exjade once daily at least 30 minutes before meals, on the same time each day. A combination of 250 mg and 500 mg tablets may be used to provide a specific dose level. The duration of treatment in this study is 12 months. The investigator muct emphasize complaince and will instruct the patients to take the Exjade exactly as prescribe.", 
                "intervention_name": "ICL670A and standard immunosupressive therapy (Cyclosporine A)", 
                "intervention_type": "Drug", 
                "other_name": "Deferasirox and standard immunosupressive therapy"
            }, 
            {
                "arm_group_label": "Conventional treatment arm", 
                "description": "Comparative group of patients with aplastic anemia and transfusion-dependent iron overload is undergoing treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)", 
                "intervention_name": "Immunosupressive therapy (Cyclosporine A)", 
                "intervention_type": "Drug", 
                "other_name": "Immunosupressive therapy (Cyclosporine A)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "Immunosuppressive Agents", 
                "Deferasirox"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Aplastic anemia, deferasirox, renal function", 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Moscow", 
                    "country": "Russian Federation", 
                    "zip": "125167"
                }, 
                "name": "Novartis Investigative Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Russia: Pharmacological Committee, Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline will be summarized descriptively for all on-treatment study visits.", 
            "measure": "Change of serum ferritin, iron transferrin saturation, serum total iron-binding capacity (TIBC)", 
            "safety_issue": "No", 
            "time_frame": "Screening, 4,8,12,16,20,24,28,32,36,40,44,48,52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818726"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of participants with adverse events as a measure of safety and tolerability", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Change of proteinuria in urinalysis over a period of 1 year treatment.", 
                "safety_issue": "Yes", 
                "time_frame": "1,2,3,4,8,12,16,20,24,28,32,36,40,44,48,52 weeks"
            }, 
            {
                "measure": "Change from baseline in creatinine clearance over a period of 1 year treatment.", 
                "safety_issue": "Yes", 
                "time_frame": "1,2,3,4,8,12,16,20,24,28,32,36,40,44,48,52 weeks"
            }, 
            {
                "measure": "Change from baseline of serum creatinine, bilirubin, ALT, AST, glucose over a period of 1 year treatment.", 
                "safety_issue": "Yes", 
                "time_frame": "1,2,3,4,8,12,16,20,24,28,32,36,40,44,48,52 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}